Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

@article{Bence2004PhaseIP,
  title={Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects},
  author={Aimee K. Bence and Eric B. Anderson and Maqbool A. Halepota and Michael A. Doukas and Phillip A. DeSimone and George A. Davis and Deborah A. Smith and Kevin Koch and Andrew G. Stead and Steve G Mangum and Carolyn J. Bowen and Neil L. Spector and Showchien Hsieh and Val R. Adams},
  journal={Investigational New Drugs},
  year={2004},
  volume={23},
  pages={39-49}
}
GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Two phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of single and multiple doses given to healthy subjects. The single dose study evaluated two groups of eight subjects in an ascending dose, 4-way cross-over, while the multiple dose study evaluated twenty-seven healthy volunteers in an ascending dose, double-blind, randomized, placebo-controlled, staggered parallel design… CONTINUE READING
40 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

  • W Xia, Liu L-H, P Ho, Spector
  • Oncogene
  • 2004
1 Excerpt

Truncated ErbB 2 receptor ( p 95 ErbB 2 ) is regulated by heregulin through heterodimer formation with ErbB 3 yet remains sensitive to the dual EGFR / ErbB 2 kinase inhibitor GW 572016

  • H Zhou, Kim Y-S, A Peletier, W McCall, HS Earp, CI Sartor
  • Oncogene
  • 2004

fects of the EGFR / HER 2 kinase inhibitor GW 572016 on EGFR - and HER 2 - overexpressing breast cancer cell line proliferation , ra - diosensitization , and resistance

  • TM Grana, CI Sartor, AD Cox
  • Int J Radiation Oncology Biol Phys
  • 2004

A phase I study of GW572016 in patients with solid tumors. (Abstract

  • HA Burris, C Taylor, +7 authors G Wilding
  • Proc Am Soc Clin Oncol
  • 2003
1 Excerpt

A phase I and pharmacokinetic study of CI - 1033 , a pan - erbB tyrosine kinase inhibitor , given orally on days 1 , 8 , and 15 every 28 days to patients with solid tumors

  • MA Garrison, A Tolcher, +11 authors L Baker
  • Semin Oncol
  • 2002

A phase I clinical and biomarker study of CI - 1033 , a novel pan - erb B tyrosine kinase inhibitor in patients with solid tumors

  • DM Shin, J Nemunaitis, +12 authors WK Hong
  • ( Abstract ) Proc Am Soc Clin Oncol
  • 2002

Similar Papers

Loading similar papers…